Abstract:Background: Triple-negative breast cancers (TNBC) exhibit major responses to dose-dense, dose-intense (DD-DI) neoadjuvant chemotherapy (NAC) (1). Although chronomodulated chemotherapy has shown efficacy and reducing toxicity in other cancers, there are no data in breast cancers (2). We report here a series of patients with TNBC treated with DD-DI NAC and analyzed the association between chemotherapy time infusion and pathological complete response rate (pCR) and residual tumor burden (RCB). Patients and Methods: Patients with non-metastatic TNBC treated at breast cancer disease center, St Louis hospital (Paris, France), with neoadjuvant DD-DI cyclophosphamide (1200 mg/m2 d1) – epirubicin (75 mg/m2 d1) q2w (SIM regimen) followed by 12 injections of paclitaxel (80 mg/m2) qw were included. Starting time of each chemotherapy infusion were systematically recorded. Primary endpoint was pCR defined as no residual invasive tumor in breast and in lymph nodes. Patients were dichotomized into "morning" and "afternoon" infusion groups, independently for "SIM" and "paclitaxel" regimens. Two timing cut-offs were defined according to: 1) median time of all infusions 2) cut-off maximizing morning/afternoon differences of RCB. Statistical differences between the two patient groups were assessed for metabolic response at 2 courses at Pet scan (breast delta SUVmax), RCB class (0-1 vs 2-3), pCR, dose reduction rate and 24-months event-free survival (24-months EFS). Results: Between January 2018 and January 2022, 93 patients were included. Median age was 51 (28-74). Majority of SIM administrations occurred between 12:00 and 15:00 and Paclitaxel administrations between 11:20 and 14:30. Median follow-up was 32.4 months. Main characteristics between "morning group" or "afternoon" groups in the SIM or paclitaxel were similar. pCR was obtained in 48.9% of the whole population. Regardless of cut-offs defined, no difference in pCR rate was observed. Similarly, no differences were observed between morning and afternoon groups in terms of either metabolic response, dose reduction rate or 24-months EFS (table 1). Conclusion: Time of DD-DI NAC infusion is not associated with differences in pCR rate nor in RCB, toxicity and EFS in patients with early TNBC. As immunotherapy combined with NAC is a new standard in TNBC, the impact of immunotherapy infusion time combined with NAC is under evaluation. References: 1. Giacchetti S et al. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer. 2014;110(6):1413-9. 2. Printezi MI et al. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. The Lancet Oncology. mars 2022;23(3) Table 1: Differences between "morning" and "afternoon" groups in SIM and paclitaxel regimen, with two timing infusion cut-offs. "SIM morning" Group "SIM afternoon" Group p-value "SIM morning" Group "SIM afternoon" Group p-value "Paclitaxel morning" Group "Paclitaxel afternoon" Group p-value "Paclitaxel morning" Group "Paclitaxel afternoon" Group p-value Median time infusion RCB differences Median time infusion RCB differences Chosen cut-off time 13:38 12:09 12:55 13:33 Number of patients n=48 n=45 n=22 n=71 n=47 n=46 n=56 n=37 pCR rate (%) 48.9 48.9 p=1.000 45.5 50.0 p=0.899 46.8 51.1 p=0.838 50.0 47.2 p=0.963 RCB class 0-1 vs 2-3 63.8 vs 36.2 62.2 vs 37.8 p=0.822 59.1 vs 40.9 64.3 vs 35.8 p=0.870 61.7 vs 38.3 64.4 vs 35.5 p=0.748 66.1 vs 33.9 58.3 vs 41.7 p=0.531 Metabolic response (%) -54.9 -54.3 p = 0.919 -54.7 -54.6 p = 0.981 -53.9 -55.3 p = 0.809 -52.8 -57.5 p= 0.415 Dose reduction rate (%) 20.8 37.8 p=0.116 27.3 29.6 p=1.000 25.5 32.6 p=0.601 25.0 35.1 p=0.412 24-months EFS (%) 92.9 87.7 p=0.76 97.9 82.6 p=0.34 84.5 92.1 p=0.15 94.2 84.4 p=0.53 Citation Format: Clementine Bouchez, Simona Catozzi, Caroline Cuvier, Laetitia Someil, Cedric De Bazelaire, Catherine Miquel, Nozha Mhamdi, Luis Teixeira, Marc Espie, Emilie Moati, Leonor Droin, Annabelle Ballesta, Sylvie Giacchetti. Effect of neoadjuvant dose-dense dose-intense chemotherapy timing infusion on complete histological response rate among patients with triple negative breast cancer (SIMCLOCK) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO4-13-06.

Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients

Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide Versus Docetaxel Plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer

Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country.

Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab

Dose-dense neoadjuvant chemotherapy of operable and locally advanced inoperable triple negative breast cancer: First results of single-centre prospective trial

Clinical observation of dose - dense chemotherapy in the postoperative treatment of triple- negative breast cancer

Real life comparison between doxorubicin and cyclophosphamide (AC) dose-dense (dd) and conventional dose AC in patients with triple negative breast cancer (TNBC) under neoadjuvant treatment.

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer

A Randomized Phase III Trial Comparing Dose-Dense Epirubicin and Cyclophosphamide (ecdd) Followed by Paclitaxel (T) with Paclitaxel Plus Carboplatin (pcdd) As Adjuvant Chemotherapy for Early Triple-Negative Breast Cancer Patients with High-Recurrence Risk.

Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer

Curative effects and prognostic evaluation on neoadjuvant chemotherapy of epirubicin combined with docetaxel for treating triple negative breast cancer

Final Result of Non-Anthracycline Containing Weekly Paclitaxel Plus Carboplatin Regimen As Neoadjuvant Chemotherapy for Breast Cancer.

Non-anthracycline-containing Docetaxel and Cyclophosphamide Regimen is Associated with Sustained Worse Outcome Compared with Docetaxel, Anthracycline and Cyclophosphamide in Neoadjuvant Treatment of Triple Negative and HER2-positive Breast Cancer Patients: Updated Follow-Up Data from NATT Study

Efficacy of Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer and Prognostic Analysis

Abstract PO4-13-06: Effect of neoadjuvant dose-dense dose-intense chemotherapy timing infusion on complete histological response rate among patients with triple negative breast cancer (SIMCLOCK)

Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer

Dose-dense versus 3-weekly ac during neoadjuvant chemoimmunotherapy for early-stage triple-negative breast cancer: GBECAM 0123 – the neo-real study

Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple negative breast cancer

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Abstract P2-12-22: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense adriamycin/cyclophosphamide in locally advanced triple negative breast cancer: A single-center real-world experience